Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIB, Multi-center, Double-blind, Placebo-controlled, Parallel Group, 52-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol, Administered With DMARDs, in Patients With Low to Moderate Disease Activity Rheumatoid Arthritis
Brief Summary: To assess the clinical efficacy and safety of certolizumab pegol as add-on therapy with stable-dose disease-modifying antirheumatic drugs (DMARDs) for achieving clinical remission in patients with moderate to low disease activity rheumatoid arthritis


Options:
A: Arm Label: Part A: SAR 100 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 100 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: Placebo qw; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B Cohort 1: Non-selected Doses; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Intervention Type: DRUG; Name: Sarilumab; Assigned to Arm(s): Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Placebo (for sarilumab); Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 150 mg q2w, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)
B: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)
C: Arm Label: Etanercept + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: Etanercept, Drug: Methotrexate | Arm Label: Etanercept Only; Type: EXPERIMENTAL; Interventions: Biological: Etanercept, Drug: Methotrexate | Intervention Type: BIOLOGICAL; Name: Etanercept; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Etanercept + Methotrexate, Etanercept Only
D: Arm Label: Certolizumab pegol 200 mg (CDP870); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg (CDP870) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D